Kolexia
Albiges Laurence Oncologie médicale
Albiges Laurence
Oncologie médicale
Gustave-Roussy
Villejuif, France
719 Activités
3.2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Néphrocarcinome Carcinomes Tumeurs du rein Métastase tumorale Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Tumeurs de l'appareil urogénital COVID-19 Récidive tumorale locale

Collaborateurs

Voir plus
Escudier Bernard
Escudier Bernard
Gustave-Roussy, Villejuif, France
Fizazi Karim
Fizazi Karim
Gustave-Roussy, Villejuif, France
Barthelemy Philippe
Barthelemy Philippe
Hôpital Civil, Strasbourg, France
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
MSD
50 collaboration(s)
Dernière en 2023
Ipsen
15 collaboration(s)
Dernière en 2023
Edimark
8 collaboration(s)
Dernière en 2022
BMS
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Essai Clinique (Roche)   20 mars 2024
‎PeerView Oncology & Hematology CME/CNE/CPE Video Podcast: Prof ...
Apple Podcast   14 mars 2024
Prof. Laurence Albiges, MD, PhD - Apple Podcasts
Apple Podcast   14 mars 2024
‎PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast: Prof. Laurence ...
Apple Podcast   14 mars 2024
‎PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast: Prof. Laurence ...
Apple Podcast   14 mars 2024
CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated ...
OncLive   01 mars 2024
CaboPoint: A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
Essai Clinique (Ipsen)   22 février 2024
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
CheckMate 914: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Essai Clinique (BMS)   12 février 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024